

RESEARCH

Open Access

Drug resistance associated genetic polymorphisms in *Plasmodium falciparum* and *Plasmodium vivax* collected in Honduras, Central America

Irina T Jovel^{1,2*}, Rosa E Mejía³, Engels Banegas³, Rita Piedade^{4,5}, Jackeline Alger⁶, Gustavo Fontecha⁷, Pedro E Ferreira⁸, Maria I Veiga¹, Irma G Enamorado⁹, Anders Bjorkman¹ and Johan Ursing¹

Abstract

Background: In Honduras, chloroquine and primaquine are recommended and still appear to be effective for treatment of *Plasmodium falciparum* and *Plasmodium vivax* malaria. The aim of this study was to determine the proportion of resistance associated genetic polymorphisms in *P. falciparum* and *P. vivax* collected in Honduras.

Methods: Blood samples were collected from patients seeking medical attention at the Hospital Escuela in Tegucigalpa from 2004 to 2006 as well as three regional hospitals, two health centres and one regional laboratory during 2009. Single nucleotide polymorphisms in *P. falciparum* chloroquine resistance transporter (*pfcr*t), multidrug resistance 1 (*pfmdr*1), dihydrofolate reductase (*pfdhfr*) and dihydropteroate synthase (*pfdhps*) genes and in *P. vivax* multidrug resistance 1 (*pvm*dr1) and dihydrofolate reductase (*pvdhfr*) genes were detected using PCR based methods.

Results: Thirty seven *P. falciparum* and 64 *P. vivax* samples were collected. All *P. falciparum* infections acquired in Honduras carried *pfcr*t, *pfmdr*1, *pfdhps* and *pfdhfr* alleles associated with chloroquine, amodiaquine and sulphadoxine-pyrimethamine sensitivity only. One patient with parasites acquired on a Pacific Island had *pfcr*t 76 T and *pfmdr*1 86Y alleles. That patient and a patient infected in West Africa had *pfdhfr* 51I, 59 R and 108 N alleles. *Pvm*dr1 976 F was found in 7/37 and two copies of *pvm*dr1 were found in 1/37 samples. *Pvdhfr* 57 L + 58 R was observed in 2/57 samples.

Conclusion: The results indicate that *P. falciparum* from Honduras remain sensitive to chloroquine and sulphadoxine-pyrimethamine. This suggests that chloroquine and sulphadoxine-pyrimethamine should be efficacious for treatment of uncomplicated *P. falciparum* malaria, supporting current national treatment guidelines. However, genetic polymorphisms associated with chloroquine and sulphadoxine-pyrimethamine tolerance were detected in local *P. vivax* and imported *P. falciparum* infections. Continuous monitoring of the prevalence of drug resistant/tolerant *P. falciparum* and *P. vivax* is therefore essential also in Honduras.

Keywords: *Plasmodium falciparum*, *Plasmodium vivax*, Chloroquine, Sulphadoxine-pyrimethamine, Single nucleotide polymorphisms and drug resistance

Background

In Honduras chloroquine is recommended for treatment of uncomplicated *Plasmodium falciparum* and *Plasmodium vivax* infection. In addition primaquine is used for treatment of *P. falciparum* gametocytes and *P. vivax* hypnozoites [1,2]. These drugs are believed to remain effective

despite being used for six decades and despite the spread of chloroquine resistance across most of the rest of the world. However, there is lack of clinical trials as well as *in vitro* studies and the proportions of resistance associated genetic polymorphisms have not been determined in Honduras or other Mesoamerican countries [3].

There are several genetic polymorphisms described in *P. falciparum* and *P. vivax* that can provide reliable data about the prevalence of drug resistance. The most relevant polymorphisms are presented below. The 76 T allele in the chloroquine resistance transporter gene (*pfcr*t) is

* Correspondence: irina.jovel@ki.se

¹Malaria Research Laboratory, Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital/Karolinska Institutet, Retzius väg 10, 171 77 Stockholm, Sweden

Full list of author information is available at the end of the article

predictive of chloroquine and amodiaquine treatment failure [4-6]. The 86Y allele of the multidrug resistance gene 1 (*pfmdr1*) has been linked with chloroquine and amodiaquine resistance and increased chloroquine inhibitory concentrations in *P. falciparum* with *pfcr1* 76 T [7]. The *pfcr1* 76 K and *pfmdr1* 86 N alleles have been associated with lumefantrine tolerance and higher lumefantrine IC50 values [8-10]. Amplifications of *pfmdr1* have been associated with mefloquine resistance, lumefantrine tolerance and reduced sensitivity to artesunate [11-13]. The triple dihydrofolate reductase (*pfdhfr*) haplotype N51I/C59R/S108N has been associated with sulphadoxine-pyrimethamine (SP) treatment failure and when dihydropteroate synthase (*pfdhps*) SNPs G437A and K540E are added, highly resistant *P. falciparum* are generated [14-18].

In *P. vivax*, the multidrug resistance gene 1 (*pvmdr1*) 976 F allele has been associated with reduced susceptibility to chloroquine and increased susceptibility to mefloquine and artesunate. However, amplifications of *pvmdr1* have been associated with reduced susceptibility to mefloquine and artesunate [18-20]. Twenty single nucleotide polymorphisms have been described in *P. vivax* dihydrofolate reductase (*pvdhfr*) including F57L, S58R, T61M and S117N/T that correspond to codons 50, 51, 59 and 108 in *pfdhfr*, respectively [21-24]. *Pvdhfr* S58R and S117N result in decreased binding of pyrimethamine [25] and quadruple (F57L, S58R, S117N and I173L) resistance associated SNPs have been associated with SP treatment failure [21-23].

The aim of the study was to determine the proportion of resistance associated genetic polymorphisms in *P. falciparum* and *P. vivax* field samples collected in Honduras.

Methods

Study setting, participants and ethics

In Honduras malaria transmission is seasonal and in 2010 there were 9,078 reported malaria cases. *Plasmodium vivax* mono-infection accounted for 88% and 12% were due to *Plasmodium falciparum* mono-infection and mixed *P. vivax* and *P. falciparum* infections. The country is divided into 20 health regions and there are 1,743 health facilities [2]. Samples were collected from patients that sought medical attention at the Hospital Escuela that is a teaching hospital in Distrito Central-Tegucigalpa, the regional hospitals in Trujillo, La Ceiba and Juticalpa, two primary health centres in Puerto Lempira and Iriona and one regional laboratory in Juticalpa. Samples were collected at Hospital Escuela between 2004 and 2006 and during 2009 at all other sites. The locations of all sites are shown in Figure 1. At the Hospital Escuela sample collection was considered to be part of routine malaria surveillance and did not involve additional sampling or collection of patient data. At the other health facilities patients who sought medical attention and were diagnosed with malaria

were invited to participate in the study after written informed consent. The study was approved by the ethical review committee of Cardio Pulmonary National Institute in Tegucigalpa, Honduras. The molecular analyses were approved by the Stockholm regional ethics board (reference number 2011/832-32/2).


Sample collection and microscopy

As part of routine practice, 3 ml of blood were collected in EDTA tubes by venepuncture at the Hospital Escuela. Thick and thin smears were made and stained using Giemsa. Slides were viewed under X100 magnification. Trained laboratory technician examined at least 100 microscopy fields before considering a sample negative. When *P. falciparum* or *P. vivax* were identified approximately 100 μ L of blood was collected on a filter paper (Schleicher & Schuell 903) that was dried, placed inside a small plastic bag and stored at room temperature. At the other health units the samples were generally collected in the same way but occasionally capillary samples were obtained by finger puncture. Microscopy was quality controlled at the National Malaria Laboratory were microscopists routinely re-examine all positive and approximately 10% of negative slides.

Sample storage, DNA extraction and amplification

DNA was extracted from the filter papers using an ABI Prism[®] 6100 Nucleic Acid Prep Station (Applied Biosystems, Fresno, CA) according to the manufacturer's instructions with minor modifications [26]. Extracted DNA was stored at -20°C.

Previously described multiplex PCR-RFLP (restriction fragment length polymorphism) methods were used to identify the following SNPs; *pfcr1* K76T, *pfmdr1* N86Y, *pfdhfr* N51I, C59R, N108T/S and *pfdhps* G437A and K540E [27]. *Pfcr1* 72-76 haplotypes were identified by PCR amplification followed by sequencing [28]. Previously described nested PCRs were used to amplify codons 917-1118 of *pvmdr1* and codons 1-238 of *pvdhfr* [19,29]. *Pvmdr1* and *pvdhfr* SNPs were then identified by sequencing. The Sequencher[™] software version 4.6 (Gene Codes Corporation, Ann Arbor, MI) was used for sequencing analysis. The *P. falciparum* 3D7 clone sequence obtained from NCBI database (*pfcr1* Gen-Bank Accession no. NC_004328) was used as reference for *pfcr1*. For *pvdhfr* the *P. vivax* ARI/Pakistan isolate sequence (Gen-Bank accession no. X98123) and for *pvmdr1* the *P. vivax* Sal-1 isolate sequence (Gen-Bank accession no. AY618622) were used as references. PCR and restriction products were resolved on 2% agarose gels (Amresco, Solon, OH). All gels were stained with ethidium bromide and visualized under UV transillumination (GelDoc[®], Biorad, Hercules, Ca, USA). PCR products were purified



and sequenced commercially (Macrogen Inc. Seoul, Korea).

Pfmdr1 and *pvmdr1* copy numbers were determined using real time PCR (ABI Prism[®] 7000 Sequence Detection System) as previously described [12,30]. All samples were run in triplicate. For *pfmdr1* 3D7, D10 and K1 clones were used as single copy calibrators and FCB and Dd2 were multiple copy controls. *Pvmdr1* single and double copy calibrators were created by the insertion of *pvmdr1* nucleotides 2751-3354 and *pvtubulin* nucleotides 860-1056 in the pCR2.1 vector using the TOPO TA-cloning kit (Invitrogen, Carlsbad, CA) at 1:1 and 2:1 proportions, respectively. The sample copy numbers were calculated using a comparative threshold method ($\Delta\Delta C_T$). Copy number > 1.6 was defined as a duplication of the aforementioned genes. Assays were repeated if the following results were obtained: copy number 1.3-1.6 or Ct value > 35 or standard deviation value > 0.5.

Power calculation and statistical analyses

This was an exploratory study and a power calculation of sample size was therefore not done. Data were entered, validated and analysed on Microsoft Excel 2003. For both species allele proportions were calculated by dividing the

number of samples with a certain allele by the number of samples with an identifiable allele at that position. Thus mixed infections contributed to the proportion of both alleles.

Results

Sample collection

At the Hospital Escuela blood samples were collected from 29 patients with *Plasmodium falciparum* mono-infection, 15 patients with *Plasmodium vivax* mono-infection and four patients with mixed infections. Two patients with *P. falciparum* mono-infection were assumed to have contracted their infections on a Pacific island and in West Africa based on their respective travel history. At the other laboratories and health centres samples were collected from four patients with *P. falciparum* and 45 patients with *P. vivax* mono-infections. Further details are shown in Table 1.

Polymorphisms in *Plasmodium falciparum*

Pfprt K76T, *pfmdr1* N86Y, *pfmdr1* copy numbers, *pfdhfr* SNPs and *pfdhps* SNPs were successfully identified in 32/37 (91%) of samples. Allele proportions are presented in Table 2. All *P. falciparum* from Honduras (n = 30) had

Table 1 Origin of samples

Municipalities	<i>P. falciparum</i>	<i>P. vivax</i>	Mix inf
Distrito Central-	29	15	4
Tegucigalpa			
Juticalpa		26	
Puerto Lempira	2	3	
Iriona	2		
Trujillo		8	
La Ceiba		8	

*Two patients contracted malaria elsewhere: A tourist who was admitted one week after arriving in Honduras from the Pacific island region where he had been travelling. A pilot who was admitted the day he came to Honduras after working and visiting Equatorial Guinea, Ghana and Cameroon during the previous three months.

the *pfprt* 72-76 CVMNK haplotype. The patient that became infected with *P. falciparum* in West Africa had the *pfprt* 72-76 CVMNK haplotype and the patient infected on a Pacific island had the SVMNT haplotype. No other *pfprt* SNPs were found in any of the sequenced fragments. Both imported cases had the *pfmdr1* 86Y allele and *pfdhfr* triple mutation 51I + 59 R + 108 N. One *pfmdr1* copy was found in all samples.

Polymorphisms in *Plasmodium vivax*

PCR amplifications of *pvmdr1* were successful in 64/64 samples. Following sequencing, codon 976 was identified in 41 samples and codon 1076 in 37 samples. Proportions of the alleles are shown in Table 3. The double mutation 976 F + 1076 L was observed in 4/37 (11%) samples. No other *pvmdr1* SNPs were found in the sequenced fragments. *Pvmdr1* gene copy numbers were successfully quantified in 61/64 samples. Two *pvmdr1* gene copies were found in one sample and one sample repeatedly had an indeterminate 1.5 copies. These results were verified by performing the real time PCR 5 times for these samples. The *pvmdr1* gene amplification was found in *P. vivax* that had the 976Y.

Pvdhfr was successfully amplified in 59/64 (92%) samples and sequencing was successful in 57 samples. Allele Proportions are presented in Table 4. The 57 L + 58 R double mutation was seen in 2/57 (3%) samples. Synonymous SNPs in codon 69 (TAT → TAC) were found in 13/57 (22%) samples. Two novel SNPs in codons 39

(CTG → TTG) and 85 (TCA → TCC) were observed in 2 (3%) and 3 (5%) samples, respectively. A repetition (ACA AGC GGT GGT GAC AAC) between amino acids 103 and 104 of *pvdhfr* was found in 5/57 (9%) of the samples.

Discussion

This is the first report on molecular markers of drug resistance from Honduras and indeed from Mesoamerica [3]. Finding no SNPs associated with CQ or SP resistance in *Plasmodium falciparum* from Honduras indicates that *P. falciparum* of Honduran origin remain CQ and SP sensitive. The results are in line with the continued efficacy of CQ seen in previous *in vitro* (1980) and *in vivo* (1980 and 1998-2000) studies [31,32]. This study thus indicates that the use of CQ in combination with primaquine for treatment of uncomplicated *P. falciparum* malaria and SP when CQ fails as recommended in the national treatment guidelines should be efficacious [1]. However, 2/2 patients with imported malaria had ≥ 3 SNPs associated with SP resistance suggesting that SP is not optimal for treating infections from regions outside Mesoamerica as is also recommended in the national treatment guidelines.

The results indicate that *pfprt* 76 K, *pfmdr1* 86 N and SNPs in *pfdhfr* and *pfdhps* associated with SP sensitivity are fixed in Honduras. This suggests that *P. falciparum* in Honduras are less susceptible to lumefantrine and possibly mefloquine compared to areas where the dominant SNPs are *pfprt* 76 T and *pfmdr1* 86Y [8-10,33]. Should Honduras wish to introduce an artemisinin-based treatment, combinations containing amodiaquine or SP might, from the point of view of drug sensitivity, be preferred over combinations containing lumefantrine or mefloquine.

The high proportion of patients with *P. falciparum* compared to *Plasmodium vivax* infection at the Hospital Escuela was most probably due patients with *P. falciparum* being referred there. The two patients with imported malaria had according to their history of travel contracted *P. falciparum* on a Pacific island and in West Africa. Finding the *pfprt* 72-76 SVMNT and CVMNK haplotypes is consistent with their respective travel histories suggesting that the resistance associated SNPs found were truly imported [34,35]. These two patients highlight the risk of

Table 2 Single nucleotide polymorphisms and amplifications in *pfprt*, *pfmdr1*, *pfdhfr* and *pfdhps*

Origin	<i>pfprt</i>	<i>pfmdr1</i>	Copy Number	<i>Pfdhfr</i>			<i>Pfdhps</i>		Number (Proportion %)
	76	86		51	59	108	437	540	
Honduras	K	N	1	N	C	S	A	K	30 (94) [§]
Pacific	T	Y	1	I	R	N	A	K	1 (3)
Africa	K	Y	1	I	R	N	G/A	K	1 (3)

*Resistance associated alleles are shown in bold

[§]All infections were acquired in Honduras

Table 3 *Pvmdr1* Y976F and F1076L haplotype proportions

Haplotypes	Y976F	F1076L	Number (Proportion %)
1	Y	F	29 (71)
2	Y	L	1 (2)
3	F	F	3 (7)
4	F	L	4 (10)
5	Y	ND	4 (10)

*Resistance associated alleles are shown in bold
 ND: Not Determined

importing drug resistant malaria to Honduras. Considering this it is worth noting that malaria is often diagnosed clinically in Honduras and that it is then treated presumptively with primaquine (0,25 mg/kg) for 5 days in addition to CQ. Primaquine reduces the gametocytes carriage time thus reducing transmission and it is certainly possible that this has contributed to stop resistant *P. falciparum* from becoming established [36,37].

CQ resistant *P. vivax* has been reported from several Asian and South American countries including Brazil, but not French Guiana [38]. In Southeast Asia the *pvm-dr1* 976 F allele has been associated with reduced susceptibility to CQ [19] and in Brazil it was found in 100% of samples (n = 28) whilst it was not found in French Guiana (n = 5) [39,40]. Finding the *pvm-dr1* 976 F allele in 7/41 (17%) *P. vivax* might thus indicate a degree of CQ tolerance but probably not resistance in Honduras [18,19,41]. In line with this, an *in vivo* evaluation conducted in Honduras between 1998 and 2000 found that 73/73 *P. vivax* infections were successfully treated with CQ and primaquine [32]. Finding two copies of *pvm-dr1* in 1/61 samples should be interpreted with caution as neither mefloquine nor artesunate are commonly used in Honduras [20]. It may however suggest the natural occurrence of this genetic change in Honduras. The prevalence of *pvm-dr1* 1076 L varies considerably across the world and although an association with CQ resistance has been proposed none has yet been found [18,19,39-42]. The proportion in Honduras (4/37) is similar to that found in Brazil (4/28). In the *pvm-dr1* fragment amplified for this study one synonymous and nine non-synonymous SNPs have been reported worldwide. Five of these SNPs have been reported from South America in studies including nine patients whereas only one was found in this study [43,44].

Table 4 *Pvdhfr* F57L, S58R, T61M and S117N/T haplotype proportions

Alleles	F57L	S58R	T61M	S117N/T	Number (Proportion %)
1	F	S	T	S	57 (97)
2	L	R	T	S	2 (3)

*Resistance associated alleles are shown in bold

Double (57 L + 117 N), triple (57 L + 58R + 117 N) and quadruple (57 L + 58R + 61 M + 117 T) *pvdhfr* mutations have been associated with SP resistant *P. vivax* [21,24,34]. In this study 2/57 samples had the double 57 L + 58 R SNPs that have previously been described in similar proportions in Asia but not in South America [21,24,29,45-48]. These SNPs may suggest a degree of tolerance but probably not resistance to SP. It is thus probable that SP should be efficacious for the treatment of *P. vivax* in Honduras [49]. However, the efficacy of SP for the treatment of *P. vivax* has not been assessed in Mesoamerica [3]. Furthermore, finding the double mutation despite a probably low consumption of SP suggests that resistance might develop rapidly if SP usage increases. A possible explanation for the occurrence of 57 L and 58 R despite the low use of SP for malaria might be that trimethoprim/sulfamethoxazole is the first line drug for treatment of acute respiratory tract infections in Honduras [50]. Two novel synonymous SNPs at codons 39 and 85, a previously described synonymous SNP at codon 69 and an insertion, were also found in *pvdhfr*. The proportion of SNP 69 (13/57) found in this study was considerably lower than that (77/90) reported from French Guiana [44].

Conclusion

Only SNPs linked to CQ or SP sensitivity were found in *Plasmodium falciparum* originating in Honduras indicating that CQ and SP should remain efficacious. Genetic polymorphisms associated with CQ and SP tolerance were found in eight (13%) and two (3%) *Plasmodium vivax* samples, respectively, suggesting a degree of tolerance. CQ and SP resistance associated SNPs were found in patients that contracted *P. falciparum* overseas highlighting the risk of importing drug resistance to Honduras. Continuous monitoring of the prevalence of drug resistant/tolerant *P. falciparum* and *P. vivax* in Honduras is, therefore, essential.

Acknowledgements

This work was supported by Swedish International Development Cooperation Agency, Department for research Cooperation (Sida-SAREC Contribution no 75007082/03). We wish to thank Laboratory Technician Wendy Lopez and Microbiologist Cinthya Bonilla for their work with sample collection at the Hospital Escuela.

Author details

¹Malaria Research Laboratory, Infectious Diseases Unit, Department of Medicine, Karolinska University Hospital/Karolinska Institutet, Retzius väg 10, 171 77 Stockholm, Sweden. ²Departamento de Parasitología, Escuela de Microbiología, Facultad de Ciencias, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras. ³Laboratorio Nacional de Malaria, Departamento de Laboratorios, Secretaría de Salud, Tegucigalpa, Honduras. ⁴Unit of Drug Resistance, Division of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, Stockholm, Sweden. ⁵Institute of Biotechnology and Bioengineering, Centre of Molecular and Structural Biomedicine, University of Algarve, Faro, Portugal. ⁶Servicio Parasitología, Departamento de Laboratorios Clínicos, Hospital Escuela;

Unidad de Investigación Científica, Facultad de Ciencias Médicas, Universidad Nacional Autónoma de Honduras, Tegucigalpa, Honduras. ⁷Maestría de Enfermedades Infecciosas y Zoonóticas (MEIZ), Escuela de Microbiología, Facultad de Ciencias, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras. ⁸Department of Microbiology, Tumor and Cell Biology (MTC), Karolinska Institutet, Stockholm, Sweden. ⁹Departamento de Bioanálisis e Inmunología, Escuela de Microbiología, Facultad de Ciencias, Universidad Nacional Autónoma de Honduras (UNAH), Tegucigalpa, Honduras.

Authors' contributions

ITJ conducted molecular work, planned and wrote the first draft of the manuscript. REM, IGE, AB and JU planned the study and participated in writing the manuscript. EB and GF were responsible for sample collection from regional hospitals and health centres and participated in writing the manuscript. JA was responsible for sample collection from the Hospital Escuela and participated in writing the manuscript. RP, PF and MIV conducted molecular work and participated in writing the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 27 October 2011 Accepted: 19 December 2011

Published: 19 December 2011

References

1. National Malaria Programme: *Malaria Guidelines in Honduras*. First edition. Tegucigalpa: Honduras Ministry of Health; 2010.
2. National Malaria Programme: *Malaria Situation in Honduras 2010*. Tegucigalpa: Ministry of Health; 2011.
3. WHO: *Global Report on antimalarial drug efficacy and drug resistance: 2000-2010*. Geneva 2010.
4. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Welles TE, Plowe CV, Coulibaly D: A molecular marker for chloroquine-resistant falciparum malaria. *NEJM* 2001, **344**:257-263.
5. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP: *Plasmodium falciparum* genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. *Am J Trop Med Hyg* 2007, **76**:844-848.
6. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P: A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. *Malar J* 2009, **8**:89.
7. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D: High-level chloroquine resistance in Sudanese isolates of *Plasmodium falciparum* is associated with mutations in the chloroquine resistance transporter gene *pfcr1* and the multidrug resistance Gene *pfmdr1*. *J Infect Dis* 2001, **183**:1535-1538.
8. Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP: *In vivo* selection of *Plasmodium falciparum* *pfmdr1* 86N coding alleles by artemether-lumefantrine (Coartem). *J Infect Dis* 2005, **191**:1014-1017.
9. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP: The role of *pfmdr1* in *Plasmodium falciparum* tolerance to artemether-lumefantrine in Africa. *Trop Med Int Health* 2007, **12**:736-742.
10. Mwai L, Kiara SM, Abdurahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A: *In vitro* activities of piperazine, lumefantrine, and dihydroartemisinin in Kenyan *Plasmodium falciparum* isolates and polymorphisms in *pfcr1* and *pfmdr1*. *Antimicrob Agents Chemother* 2009, **53**:5069-5073.
11. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S: The *pfmdr1* gene is associated with a multidrug-resistant phenotype in *Plasmodium falciparum* from the western border of Thailand. *Antimicrob Agents Chemother* 1999, **43**:2943-2949.
12. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S: Mefloquine resistance in *Plasmodium falciparum* and increased *pfmdr1* gene copy number. *Lancet* 2004, **364**:438-447.
13. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F: Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant *Plasmodium falciparum* malaria. *Clin Infect Dis* 2006, **42**:1570-1577.
14. Basco LK, Ringwald P: Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the *Plasmodium falciparum* dihydrofolate reductase-thymidylate synthase gene and *in vitro* resistance to pyrimethamine and cycloguanil. *Am J Trop Med Hyg* 2000, **62**:271-276.
15. Hyde JE: Drug-resistant malaria - an insight. *FEBS J* 2007, **274**:4688-4698.
16. Kublin JG, Dzinjalama FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV: Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis* 2002, **185**:380-388.
17. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, Naidoo I, Tibenderana J, Roper C: Emergence of a *dhfr* mutation conferring high-level drug resistance in *Plasmodium falciparum* populations from southwest Uganda. *J Infect Dis* 2008, **197**:1598-1604.
18. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, Nakeesathit S, Nair S, Newton P, Nosten F, Anderson TJ, Dondorp A, Day NP, White NJ: Gene amplification of the multidrug resistance 1 gene of *Plasmodium vivax* isolates from Thailand, Laos, and Myanmar. *Antimicrob Agents Chemother* 2008, **52**:2657-2659.
19. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piers KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN: Chloroquine resistant *Plasmodium vivax*: *in vitro* characterisation and association with molecular polymorphisms. *PLoS One* 2007, **2**:e1089.
20. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piers KA, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN: Amplification of *pvmr1* associated with multidrug-resistant *Plasmodium vivax*. *J Infect Dis* 2008, **198**:1558-1564.
21. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM: Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to *Plasmodium vivax dhfr* mutations. *Antimicrob Agents Chemother* 2002, **46**:3947-3953.
22. Imwong M, Pukrittayakamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G: Association of genetic mutations in *Plasmodium vivax dhfr* with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. *Antimicrob Agents Chemother* 2001, **45**:3122-3127.
23. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK: Dihydrofolate reductase mutations in *Plasmodium vivax* from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. *J Infect Dis* 2004, **189**:744-750.
24. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh le N, Maguire J, Bell D, O'Neil MT, Cheng Q: Amino acid mutations in *Plasmodium vivax* DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. *Am J Trop Med Hyg* 2006, **75**:617-621.
25. Kongsaree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw MD, Yuthavong Y: Crystal structure of dihydrofolate reductase from *Plasmodium vivax*: pyrimethamine displacement linked with mutation-induced resistance. *Proc Natl Acad Sci USA* 2005, **102**:13046-13051.
26. Dahlstrom S, Veiga MI, Ferreira P, Martensson A, Kaneko A, Andersson B, Bjorkman A, Gil JP: Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of *Plasmodium falciparum* (PfATP6). *Infect Genet Evol* 2008, **8**:340-345.
27. Veiga MI, Ferreira PE, Bjorkman A, Gil JP: Multiplex PCR-RFLP methods for *pfcr1*, *pfmdr1* and *pfdhfr* mutations in *Plasmodium falciparum*. *Mol Cell Probes* 2006, **20**:100-104.
28. Echeverry DF, Holmgren G, Murillo C, Higuera JC, Bjorkman A, Gil JP, Osorio L: Short report: polymorphisms in the *pfcr1* and *pfmdr1* genes of *Plasmodium falciparum* and *in vitro* susceptibility to amodiaquine and desethylamodiaquine. *Am J Trop Med Hyg* 2007, **77**:1034-1038.
29. Hawkins VN, Auliff A, Prajapati SK, Rungsirunrat K, Haparachchi HC, Maestre A, O'Neil MT, Cheng Q, Joshi H, Na-Bangchang K, Sibley CH: Multiple origins of resistance-conferring mutations in *Plasmodium vivax* dihydrofolate reductase. *Malar J* 2008, **7**:72.
30. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, Lee HW, Chen JH, Wang Y, Sattabongkot J, Han ET: Genetic polymorphism in *pvmr1* and *pvcr1*-o

- genes in relation to *in vitro* drug susceptibility of *Plasmodium vivax* isolates from malaria-endemic countries. *Acta Trop* 2011, **117**:69-75.
31. Nguyen-Dinh P, Hobbs JH, Campbell CC: **Assessment of chloroquine sensitivity of *Plasmodium falciparum* in Choluteca, Honduras.** *Bull World Health Organ* 1981, **59**:641-646.
 32. Mejía-Díaz JR, Alger J, Valenzuela-Castillo R, Jeremías-Soto R: **Evaluate the clinical and parasitological efficacy of chloroquine in the treatment of malaria in children.** *Hospital Escuela 1998-2000, Tegucigalpa, Honduras. Revista Medica de los Postgrados de Medicina* 2000, **5**:97-104.
 33. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC: **The tyrosine-86 allele of the *pfmdr1* gene of *Plasmodium falciparum* is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin.** *Mol Biochem Parasit* 2000, **108**:13-23.
 34. Mita T: **Origins and spread of *pfdhfr* mutant alleles in *Plasmodium falciparum*.** *Acta Trop* 2010, **114**:166-170.
 35. Mita T, Tanabe K, Kita K: **Spread and evolution of *Plasmodium falciparum* drug resistance.** *Parasitol Int* 2009, **58**:201-209.
 36. Barnes KI, White NJ: **Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in *Plasmodium falciparum*.** *Acta Trop* 2005, **94**:230-240.
 37. Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL: **Optimally timing primaquine treatment to reduce *Plasmodium falciparum* transmission in low endemicity Thai-Myanmar border populations.** *Malar J* 2009, **8**:159.
 38. Baird JK: **Resistance to therapies for infection by *Plasmodium vivax*.** *Clin Microbiol Rev* 2009, **22**:508-534.
 39. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU: **Recurrent parasitemias and population dynamics of *Plasmodium vivax* polymorphisms in rural Amazonia.** *Am J Trop Med Hyg* 2009, **81**:961-968.
 40. Barnadas C, Tichit M, Bouchier C, Ratsimbaoa A, Randrianasolo L, Raheerinjafy R, Jahevitra M, Picot S, Menard D: ***Plasmodium vivax dhfr* and *dhps* mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine.** *Malar J* 2008, **7**:35.
 41. Miao M, Yang Z, Cui L, Ahlum J, Huang Y: **Different allele prevalence in the dihydrofolate reductase and dihydropteroate synthase genes in *Plasmodium vivax* populations from China.** *Am J Trop Med Hyg* 2010, **83**:1206-1211.
 42. Gama BE, Oliveira NK, Souza JM, Daniel-Ribeiro CT, Ferreira-da-Cruz Mde F: **Characterisation of *pvmr1* and *pvdhfr* genes associated with chemoresistance in Brazilian *Plasmodium vivax* isolates.** *Mem Inst Oswaldo Cruz* 2009, **104**:1009-1011.
 43. Orjuela-Sanchez P, de Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR, Alecrim MG, del Portillo HA: **Analysis of single-nucleotide polymorphisms in the *crt-o* and *mdr1* genes of *Plasmodium vivax* among chloroquine-resistant isolates from the Brazilian Amazon region.** *Antimicrob Agents Chemother* 2009, **53**:3561-3564.
 44. Barnadas C, Musset L, Legrand E, Tichit M, Briolant S, Fusai T, Rogier C, Bouchier C, Picot S, Menard D: **High prevalence and fixation of *Plasmodium vivax dhfr/dhps* mutations related to sulfadoxine/pyrimethamine resistance in French Guiana.** *Am J Trop Med Hyg* 2009, **81**:19-22.
 45. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G: **Novel point mutations in the dihydrofolate reductase gene of *Plasmodium vivax*: evidence for sequential selection by drug pressure.** *Antimicrob Agents Chemother* 2003, **47**:1514-1521.
 46. Kaur S, Prajapati SK, Kalyanaraman K, Mohammed A, Joshi H, Chauhan VS: ***Plasmodium vivax* dihydrofolate reductase point mutations from the Indian subcontinent.** *Acta Trop* 2006, **97**:174-180.
 47. Zakeri S, Afsharpad M, Ghasemi F, Raeisi A, Kakar Q, Atta H, Djajid ND: ***Plasmodium vivax*: prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in *Plasmodium vivax* clinical isolates from Pakistan.** *Exp Parasitol* 2011, **127**:167-172.
 48. Zakeri S, Motmaen SR, Afsharpad M, Djajid ND: **Molecular characterization of antifolates resistance-associated genes, (*dhfr* and *dhps*) in *Plasmodium vivax* isolates from the Middle East.** *Malar J* 2009, **8**:20.
 49. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH: **Antifolates can have a role in the treatment of *Plasmodium vivax*.** *Trends Parasitol* 2007, **23**:213-222.
 50. **Strengthening Pharmaceutical Program: Situation of management of medicines supply for treatment of malaria in Central America countries. Presented to United States Agency for International Development by the SPS Program Health MSF ed. Arlington, VA; 2008.**

doi:10.1186/1475-2875-10-376

Cite this article as: Jovel et al.: Drug resistance associated genetic polymorphisms in *Plasmodium falciparum* and *Plasmodium vivax* collected in Honduras, Central America. *Malaria Journal* 2011 **10**:376.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

